IDWeek 2022
Meeting Coverage
An Inhaled IFN-ß Treatment May Decrease Risk for Long COVID-19 Symptoms
Monkeypox MVA-BN Vaccine Elicits Durable Immunity for 2 Years With Single Dose
Procalcitonin Predicts Recurrence or Death After Ventilator-Associated Pneumonia
Novel Immunoassay Stratifies Between Bacterial, Viral Infections in Children
Vaccination Status Not Associated With Acute Thromboembolism Risk in COVID-19
Antibiotic Overuse Common in Children Hospitalized With COVID-19
Preventive Interventions Are Needed for Invasive Extraintestinal E. coli Disease
Oral Capsule Effective as Fecal Microbiota Transplant Delivery Strategy
Subcutaneous Lenacapavir Effective for Patients With Multidrug-Resistant HIV
Individuals With HIV and Cognitive Impairment at Increased Risk for COVID-19 Mortality
Elevated ALT Following Hepatitis C Treatment May Indicate Treatment Failure
Antiretroviral Therapy Discontinuation Common After Regimen Switch Despite Suppression
Cefepime-Taniborbactam Superior to Meropenem for Complicated UTI
Risk Factors for Progression to Hospital-Onset C. difficile Infection in Colonized Patients
Is Fidaxomicin Superior to Vancomycin for Patients Hospitalized With C. difficile Infection?
High-Dose Superior to Standard-Dose Influenza Vaccination in Older Adults
Bictegravir/Emtricitabine/Tenofovir Alafenamide Effective for Advanced HIV
Ridinilazole Reduces C. difficile Infection Recurrence More Effectively Than Vancomycin
High-Dose Dexamethasone May Be Harmful for Patients With COVID-19
Recombinant Zoster Vaccine Confers Long-Term Protection in Older Adults
In this interim analysis, researchers evaluated patient data captured from year 4 of an extension study. The phase 3 trials were initiated in 2010 and completed in 2015, and the extension study was initiated in 2016; overall, the analysis comprised 10 years of data.
Want to read more?
Please login or register first to view this content.